首页> 外文期刊>Neuromuscular disorders: NMD >The MYODA operational seamless clinical trial design phase I to III: a new approach for rare diseases to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of BIO101 (MAS activator) in paediatric patients with a genetically confirmed diagnosis of Duchenne muscular dystrophy
【24h】

The MYODA operational seamless clinical trial design phase I to III: a new approach for rare diseases to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of BIO101 (MAS activator) in paediatric patients with a genetically confirmed diagnosis of Duchenne muscular dystrophy

机译:Myoda运营无缝临床试验设计阶段I至III:一种罕见疾病的新方法,以评估小儿患者Bio101(MAS活化剂)的安全,疗效,药代动力学和药效学患者的遗传证实患者诊断Duchenne肌营养不良症

获取原文
获取原文并翻译 | 示例
           

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号